In a meanwhile, epidermal growth factor receptor (EGFR) signaling promotes aerobic glycolysis through the phosphoinositide 3-kinase/AKT or RAS/ mitogen-activated protein kinase pathway [6], and EGFR TKI erlotinib reverted aerobic glycolysis in cancer cell line [7] - Current concepts in The identification and characterisation of Rho Kinase Inhibitors

In a meanwhile, epidermal growth factor receptor (EGFR) signaling promotes aerobic glycolysis through the phosphoinositide 3-kinase/AKT or RAS/ mitogen-activated protein kinase pathway [6], and EGFR TKI erlotinib reverted aerobic glycolysis in cancer cell line [7]. Against this backdrop, phase II clinical trials evaluating the efficacy and safety of the combination of GSK2838232A bevacizumab plus erlotinib … Continue reading In a meanwhile, epidermal growth factor receptor (EGFR) signaling promotes aerobic glycolysis through the phosphoinositide 3-kinase/AKT or RAS/ mitogen-activated protein kinase pathway [6], and EGFR TKI erlotinib reverted aerobic glycolysis in cancer cell line [7]